1215074-37-5

Basic information

• Product Name: 7-bromo-Pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione
• Synonyms: 7-bromo-Pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione;7-BROMOPYRIDO[3,2-D]PYRIMIDINE-2,4(1H,3H)-DIONE（WS203957）;7-Bromopyrido[3,2-d]pyrimidine-2,4-diol
• CAS NO: 1215074-37-5
• Molecular Formula: C₇H₄BrN₃O₂
• Molecular Weight: 242.02956
• Mol File: 1215074-37-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.851±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.89±0.20(Predicted)
• CAS DataBase Reference: 7-bromo-Pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 7-bromo-Pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione(1215074-37-5)
• EPA Substance Registry System: 7-bromo-Pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione(1215074-37-5)

Safety Data

• Hazardous Substances Data: 1215074-37-5(Hazardous Substances Data)

Upstream product

• 870997-85-6 3-amino-5-bromo-pyridine-2-carboxylic acid 
• 57-13-6 urea 
• 1334405-60-5 ethyl 3-amino-5-bromopyridine-2-carboxylate 
• 573675-25-9 5-bromo-3-nitropyridine-2-carbonitrile 
• 669066-89-1 3-amino-5-bromopyridine-2-carboxylic acid amide 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 60-35-5 acetamide 

Downstream Products

• 1215074-41-1 7-bromo-2,4-dichloropyrido[3,2-d]pyrimidine 
• 1374203-79-8 N,N-dimethyl-4-{3-[4-(4-morpholin-4-yl-7-pyrimidin-5-yl-pyrido[3,2-d]-pyrimidin-2-yl)-phenyl]-ureido}-benzamide 

Relevant articles and documents

PYRIDOPYRIMIDINES AND METHODS OF THEIR USE

Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.

CD73 INHIBITORS

Disclosed are compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions, and compositions containing the compounds.

SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES

The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.